Pemetrexed Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Pemetrexed Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

Market Dynamics

Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to support global pemetrexed market growth over the forecast period.

For instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.

High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for Pemetrexed for its treatment and support global pemetrexed market growth over the forecast period.

For instance, according to the data published by American Society of Clinical Oncology, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.

Furthermore, key players in the market are dedicated to expand the indication of its Pemetrexed drugs in order to increase its sale and generate high revenues. For instance, in June 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.

Key features of the study:

  • This report provides in-depth analysis of Pemetrexed market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global Pemetrexed market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and Others
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Pemetrexed market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Pemetrexed market
Detailed Segmentation:
  • Global Pemetrexed Market, By Strength :
  • 100 mg
  • 500 mg
  • Global Pemetrexed Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Pemetrexed Market, By Region:
  • North America
  • By Strength :
  • 100 mg
  • 500 mg
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Europe
  • By Strength :
  • 100 mg
  • 500 mg
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Strength :
  • 100 mg
  • 500 mg
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • By Strength :
  • 100 mg
  • 500 mg
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
  • By Strength :
  • 100 mg
  • 500 mg
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Strength :
  • 100 mg
  • 500 mg
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Eli Lilly and Company *
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Stada Arzneimittel AG
  • Eagle Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Strength
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Novel Product Launch/Approval
Merger-Acquisition Scenario
PEST Analysis
Regulatory Scenario
Reimbursement Scenario
Epidemiology
4. Global Pemetrexed Market, By Strength, 2018 – 2026 (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
100 mg
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
500 mg
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
5. Global Pemetrexed Market, By Distribution Channel, 2018 – 2026 (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
6. Global Pemetrexed Market, By Region, 2018 – 2026 (US$ Mn)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2026
North America
Market Size and Forecast, By Strength, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
U.S.
Canada
Europe
Market Size and Forecast, By Strength, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Strength, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of APAC
Latin America
Market Size and Forecast, By Strength, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Strength, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
Central Africa
South Africa
North Africa
Middle East
Market Size and Forecast, By Strength, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
GCC
Israel
Rest of Middle East
7. Competitive Landscape
Heat Map Analysis
Company Profiles
Eli Lilly and Company
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Stada Arzneimittel AG
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Eagle Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
8. Section
References
Research Methodology
About us and Sales Contact
*Browse 18 market data tables and 20 figures on “Pemetrexed Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook